Mark Emberton, MD, FRCS
Mark Emberton is Professor of Intervention Oncology within the Division of Surgery and Dean of the Faculty of Medical Science at University College London. He is clinically active and holds the position of Honorary Consultant Urologist at University College London Hospitals NHS Trust where he works as a specialist in prostate cancer.
His academic work has focused on developing novel diagnostic strategies and new therapies for men with prostate cancer. His research has resulted in the transformation of both the diagnostic and therapeutic pathways. These have been incorporated into international guidelines.
He has published over 500 peer review papers, holds a large grant portfolio, and lectures widely around the world and holds international honorary professorships.
He is a founding Pioneer of the charity Prostate Cancer UK.
Clement Orczyk, M.D.
Dr. Clement Orczyk is Associate Professor of Urology at University College London, Department of Targeted Intervention Division of Surgery & Interventional Science. He is the clinical lead of the diagnostic and focal therapy team for prostate cancer at University College London Hospitals, where he holds the position of Honorary Consultant Urological Surgeon. While he delivers focal therapy interventions in his routine practice, he has led and participated in many innovative clinical trials using various form of energies for focal therapy treatment. Dr. Orczyk was educated at University of Paris and received his M.D from Universite de Caen Basse Normandie as well as Master of Science in MPH, Law, Economy, Health Policy and Social Sciences, and a Ph.D. in Biology Clinical Research, Technology and Innovation, Health. He joined UCL in 2015.
His academic work is focused on increasing the risk/ benefit ratio of prostate cancer management for patients. He currently leads clinical and translational trials on biomarker, imaging and treatments intervention, holding grants in that field. He is an invited speaker on this topic in international conferences and has published in major peer-reviewed journals.
Fernando Bianco, M.D.
Dr. Bianco is the Founder & CEO of Focalyx, an imaging fusion company that has developed a patented medical device for prostate cancer ablation in the office setting.
Dr. Bianco is a Urologic Oncologist and a member of the Urology Specialist Group in Miami. He also serves as Investigator In-Chief for the Urological Research Network, a not-for-profit research organization in Miami with the mission to engage and conduct high impact investigations to promote and enhance the field of urology and patients’ quality of life.
Trained at Wayne State University and Memorial Sloan-Kettering, Dr. Bianco served as Head of the Prostate program, Chair of Urology Oncology at George Washington University and Associate Professor at Columbia University. He was the founder and Director of Robotic Surgery for Mount Sinai Medical Center, and Columbia University Division of Urology.
His work has been awarded on numerous occasions by the American Urological Association, the Society of Urological Oncology, and the American Society of Clinical Oncology. He serves on the review panel and editorial board of numerous peer reviewed journals, including the Journal of Urology, Urology Oncology, Journal of Clinical Oncology, Urology, Cancer, Lancet Oncology and European Urology. To date, Dr. Bianco has published over 100 scientific articles and has written over 30 chapters and reviews.
Samir Taneja, M.D.
Samir S. Taneja, MD is a Professor of Urologic Oncology and Radiology and Director of the Division of Urologic Oncology at the NYU Langone Medical Center. Dr Taneja has over 30 years in clinical practice and is nationally renowned as a leader in the treatment and research of urologic cancers. His past research has received funding through the National Institutes of Health, Department of Defense, and the Prostate Cancer Foundation. In recent years, his clinical research has been on prostate cancer diagnostics, with particular focus on the use of imaging in the detection, risk stratification, and therapy of prostate cancer. He has lectured throughout the world and is internationally renowned as an expert in the integration of MRI into clinical practice paradigms.
Dr. Taneja has served on many national organizations and chaired many task forces including the American Board of Urology Exam Committee and the Society of Urologic Oncology Executive Board, and has overseen the Urologic Research Society. He has authored over 250 articles, 25 book chapters, and six textbooks and periodicals on urologic cancer and urologic surgery. He is on the editorial board of the consulting editor and an editor of various urology journals, including European Urology and Journal of Urology. He is editor of the 3rd, 4th, and upcoming 5th, and upcoming 6th editions of Taneja’s Complications of Urologic Surgery: Prevention and Diagnosis, one of the most widely read textbooks in American urology.
He received his undergraduate and medical education at Northwestern University Medical School. He completed his surgical and urologic training at the University of California at Los Angeles and joined the NYU faculty in 1996.
Ashish Kamat, M.D.
Dr. Kamat has been named by Expertscape as the world’s the top-rated expert in urinary bladder neoplasms. Dr. Kamat has extensive experience with cystoscopic procedures, has been a principal investigator for multiple oncology and urology clinical studies for both drugs and devices, and has been involved in blue light cystoscopy studies since 2007. Dr. Kamat is an Endowed Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center (MDACC); Associate Cancer Center Director, RFHNH in Mumbai, and President of International Bladder Cancer Group (IBCG) and International Bladder Cancer Network (IBCN). He is Associate Editor for European Urology Oncology, directed the MDACC Urologic Oncology Fellowship from 2005-2016, and is an alumnus of the American Urological Association Leadership Program. Dr. Kamat received his medical degree at the University of Bombay, India’s Seth G. S. Medical College & King Edward Memorial Hospital and completed a fellowship in Urologic Oncology at the MD Anderson Cancer Center. Dr. Kamat focuses on bladder cancer, immunotherapy and organ sparing therapies. He has led several national and international studies, which have been reported in high impact journals. Dr. Kamat has over 300 publications, is listed in ‘Who’s Who in Medicine’ and ‘Best Doctors in America’, and has won the ‘Compassionate Doctor Award’ from patient groups.
Trinity J. Bivalacqua, MD, PhD
Trinity J. Bivalacqua, MD, PhD. is the Director of Urologic Oncology and Co-Director of the Genitourinary Cancer Service Line in the Abramson Cancer Center at Penn Medicine, a facility of the Hospital of the University of Pennsylvania. He received his graduation degrees from Tulane University and trained at the Johns Hopkins Hospital. He was the R. Christian B. Evenson Professor of Urology at Johns Hopkins prior to moving to University of Pennsylvania. Dr. Bivalacqua has extensive experience in management of non-muscle invasive bladder cancer and has designed and led multiple clinical trials evaluating novel intravesical agents and imaging techniques to assess bladder tumors. His research focuses on cancer immunology of urothelial cancer and tissue engineering approaches to regenerate the lower urinary tract. Dr. Bivalacqua has received multiple awards and recognition for his leadership in urologic oncology, sexual dysfunction and translational research including the American Urological Association (AUA) Rising Star Award and the AUA Gold Cystoscopy Award which is given to the individual who has contributed the most to the field of Urology within the first ten years of practice. He is known in the medical community for performing complex surgeries and cutting-edge translational research and works with a number of national society boards and advocacy groups including the AUA, the Sexual Medicine Society of North America, the Society of Urologic Oncology, International Bladder Cancer Group (IBCG), International Bladder Cancer Network (IBCN) and the Bladder Cancer Advocacy Network.
Richard Matulewicz, MD, MSCI, MS
Dr. Richard Matulewicz is a urologic oncologist and surgeon at Memorial Sloan Kettering Cancer Center (MSKCC), specializing in urologic cancers such as prostate, kidney, bladder, and testicular cancer. He completed medical school at Tufts University and his urology residency at Northwestern University Feinberg School of Medicine, followed by a clinical fellowship in urologic oncology at MSKCC and a research fellowship at NYU in population health and health services research. He is an expert in open, endoscopic, and robotic surgeries for urologic cancers.
